Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610371 | 0.85 | ABL1 (0.64) | ABL1SLC6A3SLC6A4NR4A2MAPT | |
| SCHEMBL30954389 | 0.83 | ALDH1A1 (0.42) | ABL1MAPTNPC1ALDH1A1KDM4E | |
| SCHEMBL6100118 | 0.82 | ABL1 (0.70) | ABL1SLC6A3SLC6A4NR4A2MAPT | |
| SCHEMBL20872668 | 0.82 | ALDH1A1 (0.41) | ABL1NR4A2MAPTNPC1KMT2A | |
| SCHEMBL16219703 | 0.81 | SLC6A3 (0.49) | ABL1SLC6A3SLC6A4NR4A2MAPT | |
| SCHEMBL861495 | 0.81 | PTPN2 (0.54) | SLC6A3NR4A2MAPTALDH1A1HTT | |
| SCHEMBL4363906 | 0.81 | ABL1 (0.62) | ABL1SLC6A3SLC6A4NR4A2MAPT | |
| SCHEMBL5096350 | 0.81 | CYP4F2 (0.51) | MAPTNPC1KMT2AKDM4EF2R | |
| SCHEMBL2477523 | 0.81 | CNR1 (0.42) | ABL1MAPTNPC1MEN1KMT2A | |
| SCHEMBL21102263 | 0.80 | SLC6A3 (0.55) | ABL1SLC6A3SLC6A4NR4A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854631-B | 4-Aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2025-04-15 | — | — | CN | claimed |
| CN-116854631-A | 4-aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2023-10-10 | — | — | CN | claimed |
| EP-4106028-B1 | ORGANIC ELECTRONIC DEVICE COMPRISING A COMPOUND OF FORMULA (I), DISPLAY DEVICE COMPRISING THE ORGANIC ELECTRONIC DEVICE AS WELL AS COMPOUNDS OF FORMULA (I) | NOVALED GMBH (DE) | 2026-05-27 | — | — | EP | disclosed |
| CN-117603220-B | Organic compound, organic electroluminescent device and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4063466-B1 | ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE INCLUDING SAME | SAMSUNG SDI CO LTD (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4356445-B1 | ORGANIC ELECTRONIC DEVICE COMPRISING A COMPOUND OF FORMULA (I), DISPLAY DEVICE COMPRISING THE ORGANIC ELECTRONIC DEVICE AS WELL AS COMPOUNDS OF FORMULA (I) | NOVALED GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-12433152-B2 | Compound for organic optoelectronic device, composition for organic optoelectronic device, organic optoelectronic device and display device | SAMSUNG SDI CO., LTD. (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| CN-1061408-A | Saturated hydroxyalkyl quinolinic acids as leukotriene antagonists | MERCK FROSST CANADA INC (US) | 1992-05-27 | — | — | CN | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | ABL1 3090/4885SLC6A3 566/4885SLC6A4 1229/4885 |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | ABL1 15/4885SLC6A3 1884/4885SLC6A4 2678/4885 |
| US-12433152-B2 | Compound for organic optoelectronic device, composition for organic optoelectronic device, organic optoelectronic device and display device | OCIAD2, OCIAD1, OXER1 | ABL1 2099/4885SLC6A3 3306/4885SLC6A4 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.